

SUBJECT INDEX

- A,B,H antigens
 - formation and structure of, 206, 207
 - in situ modification of, 206-208
- ABO antigens, in renal allograft survival, 172-174
- ABO blood groups, conversion of, 206-212
- Acquired immune deficiency syndrome, FcR blocking factor and, 184-185
- Acropathy, 142-143
- Adsol, 47
- Agammaglobulinemia, 87
- AIDS, *see* Acquired immune deficiency syndrome
- AIHA, *see* Autoimmune hemolytic anemia
- Allograft survival, renal, 171-177
 - see also* Renal transplantation
- Alloimmunization, leukocyte-depleted red cells and platelets and, 124, 180-183, 185
- Alloreactive clones, inactivation of, 177
- Alpha-1 antiplasmin, 265-266
- Alpha-1 antitrypsin, 265-266
- Amino acid sequence
 - of ATIII, 265
 - of DAF, 14
 - of LFA-3, 13
 - of Rh gene, 1-2
- Anemia
 - Autologous transfusion and, 294
 - hemolytic, autoimmune, 142-143
 - neonatal, 39-41
 - perioperative red cell transfusion and, 63-64
 - sports, 241
- Antibiotics, GTX transfusion therapy and, 49-52
- Antibody
 - production of, blood transfusion and, 177
 - to Rh40, 2
 - to Rh41, 2-3
 - to Rh42, 3
 - to Rh43, 3-4
 - to Rh44, 4
 - to Rh45, 4-5
 - to Rh46, 5
 - to Rh47, 5-6
- Anti-coagulant solutions, 46
- Antifactor Xa activity, ATIII deficiency and, 257
- Antigen-presenting cells, 180-181
- Anti-HCV, 78-80
- Anti-JMH, antibody to, 132-133
- Antithrombin III, 253-254
 - amino acid homology of, 265
 - heparin interaction with, 267-268
 - mutant, 266-267
 - structure and function of, 264-265, 268
 - thrombin interaction with, 265-268
- Antithrombin III concentrates, 254
- Antithrombin III deficiency, 253-261
 - acquired, 256-261
 - classification of, 271-277
 - general considerations for, 253-254
 - inherited, 254-256, 264-277
 - molecular pathology of, 264-277
 - in neonates, 256-257
 - pregnancy and, 255-256
 - surgery and, 256-268
 - type I, 273
 - type II, 273-275
 - type III, 275-277
- Antithrombin III gene, 268-271
 - expression of, 271
 - nucleotide sequence of, 270
 - structure of, 268
- Antitrypsin Pittsburgh, 265
- AO, *see* Available oxygen
- APCs, *see* Antigen-presenting cells
- Apnea, red cell transfusion for, 42
- ATIII, *see* Antithrombin III
- Autoimmune disorders, IV IgG for, 98-99
- Autoimmune hemolytic anemia, 142-143
 - see also* Anemia
- Autologous transfusion, 63, 66, 292-302
 - anemia and, 294
 - controversies in, 298
 - criteria for, 298-300
 - economic issues in, 301-302
 - frozen storage of, 293-294
 - indications for, 300
 - intraoperative, 296-297
 - perioperative hemodilution for, 294-296
 - postoperative, 297-298
 - preoperative donation for, 292-294
 - testing for, 300-301
 - unused, disposition of, 301
- Available oxygen, measurement of, 41
- Bacterial lectins, 60
- B cell, IL-1 and, 198
- Blood doping, 241, 242
- Blood filter
 - history of, 187-188
 - types of, 188
- Blood irradiation, 49, 182, 185
- Blood loss
 - intraoperative, 66
 - in neonates, 42-44
- Blood products
 - adverse effects of, 109-111
 - type and volume of, 248
- Blood salvage, intraoperative, 66
- B lymphocyte, function of, 194
- BMT, *see* Bone marrow transplantation
- Bone marrow transplantation
 - IV IgG for, 93
 - lectins and, 59
- Breast cancer, effect of blood transfusion on, 246
- BRIC 125 glycoprotein, 16-20
- CA, *see* Cold agglutination
- CD 2, LFA-3 binding to, 13
- CD4 cells, 181

- CD8 cells, 181
- CD44 glycoprotein, 15-16, 18-20
- Cell cycle, myc gene and, 26
- Cell differentiation
 - fos gene in, 32-34
 - myc gene in, 28-31
 - ras proteins in, 34-35
- Cervical cancer, effect of blood transfusion on, 247
- CFA I, *see* Colonisation factor antigen I
- Ch antigen, antibodies to, 133-134
- CHD, *see* Cold hemagglutinin disease
- Children
 - acute ITP in, 94-98
 - acute PCH in, 219-227
- Chromosome 1
 - CR1 and, 15
 - DAF and, 14
 - LFA-3 and, 14
- Chromosome 3, BRIC 125 glycoprotein and, 16
- Chromosome 19, OK^a and, 17
- Chronic lymphocytic leukemia
 - IV IgG for, 91-92
 - see also* Leukemia virus, 91-92
- Chymotrypsin inhibitor, 265-266
- CI-inhibitor, 265-266
- CJ-defined antigen, 7
- CLL, *see* Chronic lymphocytic leukemia
- CM-defined antigen, 6-7
- CMV, *see* Cytomegalovirus
- Cold agglutination, 140-161
 - antibody characteristics in, 157-159
 - antigens recognized by, 143-157
 - chronic, 141-142, 160-161
 - clinical conditions associated with, 140-142
 - FL antigens and, 149-152
 - general considerations for, 140-161
 - Ii antigens and, 144-149
 - Li antigens and, 152
 - low-titer, 140
 - Lud antigens and, 152
 - malignant, 142
 - manifestations of, 142-143
 - postinfectious, 140, 159
 - Pr antigens and, 152-156
 - Sa antigens and, 156-157
 - serologic test for, 143
 - Vo antigens and, 152
- Cold hemagglutinin disease, 226
- Colonisation factor antigen I, 60
- Colorectal carcinoma, effect of blood transfusion on, 244-246
- Congenital gammaglobulin deficiency
 - IgG for, 87-89, 91
 - see also* Gammaglobulin
- "Cow technique," for neonates, 45
- CR1, 15, 18-20
- Crawford, *see* Rh43
- Cromer-related antigens, DAF and, 15
- Cryoglobulinemia, 143
- Cryopreservation, 45
- Cryoprotection, 121-125
- Cryptantigens, lectins and, 58
- Crythropoietin, administration of, 294
- Cs^a antigen, antibodies to, 128-130
- Cytochalasin B, Fc gamma receptors and, 284
- Cytokines, 194, 195
 - see also* Interleukin-1
- Cytomegalovirus
 - blood transfusion and, 187-189
 - cold agglutination and, 141
 - IV IgG for, 93
- DAF, *see* Decay accelerating factor
- Dav, *see* Rh47
- Decay accelerating factor, 14-15, 18-20
- Dialysis, frozen red cells for, 124
- DIC, *see* Disseminated intravascular coagulation
- Diphosphoglycerate, 238, 239
- Directed donations, 291-292
- Disseminated intravascular coagulation, ATIII infusion and, 259-261
- DL, *see* Donath Landsteiner test
- DNA virus, oncogenic, 24
- Dolichos biflorus*, 57
- Donath Landsteiner test, 222-225
- Duffy blood group system, LFA-3 and, 14
- 12E7, 17-20
- EBV, *see* Epstein-Barr virus
- Epstein-Barr virus, cold agglutination and, 140-141
- Erythroid differentiation, myc gene and, 28
- Erythroid marrow progenitor cells, 237-238
- Erythropoiesis, red cell transfusion and, 40-41
- Erythropoietin, 237
 - production of, 240-241
 - red cell production and, 238-239
 - at various hematocrits, 240-241
- Escherichia coli*, DAF and, 15
- Fab regions, of IgG, 82-83
- Factor IX concentrates, ATIII deficiency and, 257
- Familial venous thromboembolism, 254-256
 - see also* Antithrombin III deficiency
- Fc fragment, of IgG, 83-84
- Fc gamma receptor(s), 282-287
 - Fc gamma RI as, 282-284
 - Fc gamma RII as, 284-286
 - Fc gamma RIII as, 286-287
- FcR blocking factor, 184-185, 186
- Fib 75.1, 18
- Filter, microaggregate, 52
- FL antigens, cold agglutination and, 149-152
- Forensic serology, lectins in, 58
- Fos gene, 31-34
- FPTT, 6
- Frozen blood, 45
- Frozen red cells, 121-125
 - for autologous transfusion, 293-294
 - clinical applications for, 123-125
 - history of, 121-122
 - shortcomings of, 122-123
 - theory of, 121

- Gammaglobulin, 82-111
 for alloimmune disorders, 98-99
 antibody synthesis and, 107-108
 for autoimmune disorders, 98-99
 for bone marrow transplantation, 93
 cell clearance and, 83-85
 for CLL, 91-92
 for congenital gammaglobulin deficiency, 87, 89-91
 for critically ill, 93
 for cytomegalovirus, 93
 discovery of, 82
 half-life and catabolism of, 85
 home infusion pump for, 87
 as immune replacement, 87-94
 as immune suppressant, 95-106
 infection transmission by, 109-111
 for inflammatory illnesses, 99
 ISG and, 85-87, 91
 for ITP, 85, 96-98, 100-108
 licensed preparations of, 87, 88-91
 low-dose, 85
 for multiple myeloma, 92
 for neonates, 92-93
 optimum dose of, 89, 91
 for partial immunodeficiency, 91
 platelet-associated, 101, 106
 purification for IV use of, 85-91
 for secondary immunodeficiency, 91-93
 side effects of, 108-111
 for specific immune prophylaxis, 91
 structure and function of, 82-83
 subclasses of, 83-84
- Gamma-interferon, Fc gamma receptor and, 283-285
- Gastric cancer, effect of blood transfusion on, 247
- Gastrointestinal mucosa, DAF and, 15
- Gliogenesis, PDGF in, 35-36
- Glucocorticoids
 Fc gamma receptor and, 283
 IL-1 and, 202
- Glycoproteins, red cell membrane, *see* Red cell membrane glycoprotein(s)
- Glycosylphosphatidylinositol tail
 DAF and, 13
 LFA-3 and, 13
- GPI tail, *see* Glycosylphosphatidylinositol tail
- Gram-negative bacteria, IL-1 and, 199-200
- Granulocyte transfusion therapy, for neonates, 49-52
- Growth factors
 erythroid progenitors and, 237
 myc gene and, 26-27
 oncogenes and, 25
- GTX, *see* Granulocyte transfusion therapy
- Gy^a antigen, antibodies to, 134-135
- HDN, *see* Hemolytic disease of the newborn
- Hematocrit
 accuracy of, 237
 optimal, 241
- Hemodilation
 intraoperative, 66
 perioperative, 294-296
- Hemoglobin
 from artificial RBC, 215-216
 conjugated, 215
 cross-linking of, 213-214
 erythropoietin and, 237-241
 future research on, 216
 intramolecular cross-linking of, 215
 microencapsulation of, 215-216
 modified, as RBC substitute, 213-216
 nephrotoxicity and, 213
 oncotic effects of, 215
 optimal, 237-242
 optimal level for adults, 239
 optimal level for athletes, 241-242
 oxygen transport and, 237, 239-240
 red cell mass function and, 237-239
- Hemoglobinuria, *see* Paroxysmal cold hemoglobinuria, acute
- Hemolytic disease of the newborn, 4-5
- Hemorrhage, neonatal, transfusion therapy for, 47-49
- Heparin
 antithrombin activity of, 264
 ATHI and, 253-254, 257, 267-268
- Heparin cofactor, *see* Antithrombin III
- Hepatitis C virus, 78-80
- Hepatitis virus, *see* Non-A, non-B hepatitis virus
- High-titer, low-avidity antibodies and antigens, 128-137
 anti-JMH, 132-133
 Ch and Rg, 133-134
 Cs^a and Yk^a, 128-130
 Kn and McC, 130-132
 other, 134-135
 serologic problems due to, 135-137
 titration results with, 136
- HIV, *see* Human immunodeficiency virus
- HLA antigens, in renal allograft survival, 171-173
- Hr_L, 7
- Hr_o, 7
- HTLA, *see* High-titer, low-avidity antibodies and antigens
- Human immunodeficiency virus
 cold agglutination and, 141
 IV IgG transmission of, 110-111
- Hy antigen, antibodies to, 134-135
- Hyperbilirubinemia, neonatal, 46
- Idiopathic thrombocytopenic purpura, IgG for, 85, 96-98, 100-108
- IgA deficiency, IV IgG for, 109
- IgG, *see* Gammaglobulin
- IgG antibody, Fc gamma receptor and, 282-287
- Ii antigens, cold agglutination and, 144-149
- IL-1, *see* Interleukin-1
- IL-2, *see* Interleukin-2
- Immune precipitation, for Rh protein isolation, 8-9
- Immune response, mechanisms of, 181
- Immune serum globulin, 85-86
 for congenital gammaglobulin deficiency, 89
 gammaglobulin vs., 86, 87, 91
 side effects of, 108-111
- Immune thrombocytopenic purpura, transfusion therapy for, 48-49

- Immunoglobulins
 - classes of, 82
 - lectins for, 60
- Immunoglobulin therapy, for thrombocytopenia, 48
- Immunosuppression
 - clinical hazards of, 186-187
 - leukocyte-depleted red cells and platelets and, 183-187
 - transfusion-induced, 176-177, 248-249
- Inab phenotype erythrocytes, DAF and, 15
- In blood group system, CD44 and, 16
- Infant status, transfusion therapy and, 43
- Infection
 - cold agglutination following, 159
 - GTX transfusion therapy for, 49-52
 - IV IgG in etiology of, 109-111
 - transfusion and, 187-189
- Inflammation
 - IL-1 in, 199-201
 - IV IgG for, 99
- Interleukin-1, 194-203
 - action of, 200-201
 - B cells and, 197-198
 - biochemical properties of, 195
 - biology of, 195-196
 - general considerations for, 194, 202-203
 - historical background for, 194-195
 - in immunological response, 196-199
 - in inflammation, 199-201
 - molecular cloning and properties of, 195-196
 - monocytes and, 198
 - regulatory mechanisms for, 201-202
 - sources of, 195
 - T lymphocyte and, 197-198
 - transfusion reactions and, 202
- Interleukin-2, 181
- Intracranial hemorrhage, neonatal, transfusion therapy for, 47-49
- ISG, *see* Immune serum globulin
- ITP, *see* Idiopathic thrombocytopenic purpura

- Kawasaki disease, IV IgG for, 99
- Kidney transplantation, 171-177
 - see also* Renal transplantation
- Klebsiella, GTX transfusion therapy for, 50-52
- Kn antigen, antibodies to, 130-132

- LAF, *see* Lymphocyte activating factor
- Lectins, 55-62
 - abnormal red cell membranes and, 58
 - applications for, 57-60
 - bacterial, 60
 - binding of, 56
 - bone marrow transplantation and, 59
 - cryptantigens and, 58
 - definition of, 55
 - with dual specificity, 57
 - in forensic serology, 58
 - future trends for, 60
 - Gal beta 1-3 GalNAc and, 57
 - history of, 56
 - for immunoglobulins, 60
 - inhibition of, 55-56
 - for leukocytes, 59-60
 - polyagglutinability and, 59
 - as precipitins, 59
 - for red cell antigens, 57
 - in secretor tests, 57-58
 - sialic acid specific, 60
 - sources of, 55
- Leukemia, lymphocytic, chronic, IV IgG for, 91-92
- Leukemia virus, oncogenesis by, 24-25
- Leukocyte-depleted red cells and platelets, 180-190
 - alloimmunization and, 124, 180-183, 185
 - frozen red cells and, 123-124
 - general considerations for, 180, 189-190
 - immunosuppression and, 183-187
 - methodology for, 187-188
 - viral contamination and, 188-189
- Leukocytes, lectins for, 59-60
- Lewis system, in renal allograft survival, 174-175
- LFA-3, *see* Lymphocyte function-associated antigen 3
- Li antigens, cold agglutination and, 152
- Livedo reticularis, 143
- Lud antigens, cold agglutination and, 152
- Lung cancer, effect of blood transfusion on, 246-247
- Lutheran blood group system, CD44 and, 16
- LW blood group system, OK^a and, 17
- Lymphocyte activating factor, 194-195
- Lymphocyte function-associated antigen 3, 13-14, 18-20
- Lymphoid differentiation, myc gene and, 28-29

- Macrophages, Fc gamma receptors on, 282-287
- Major histocompatibility complex molecules, 181
- Malignancy, effect of transfusion on, 186-187
- Marrow precursor cells, 237
- McC antigen, antibodies to, 130-132
- Megakaryocytes, IgG effect on, 108
- MER2, CD44 and, 16
- MHC, *see* Major histocompatibility complex molecules
- Microaggregate filter, 52
- MIC2 X, 12E7 and, 17-18
- MIC2 Y, 12E7 and, 17-18
- Monoclonal antibodies
 - Fc gamma receptors and, 282-283, 286
 - red cell glycoproteins and, 13
 - Rh blood system and, 8
- Monocytes
 - Fc gamma receptors on, 282-287
 - IL-1 and, 198
- Multi-pack systems for transfusion therapy, in neonate, 45
- Multiple myeloma, IV IgG for, 92
- Multiple sclerosis, CD44 and, 16
- Myb gene, 31
- Myc gene, 26-31
- Mycoplasma pneumoniae*, cold agglutinin following, 140
- Myeloid/macrophage differentiation, myc gene and, 29-30

- NANBH, *see* Non-A, non-B hepatitis virus
- Neonate
 - anemia in, 39

- anti-coagulants for, 46
- blood loss in, 42-44
- booster transfusion for, 41-42
- clinical problems in, 41-42
- donor exposure in, 39, 44-45
- frozen blood for, 45
- guidelines for treatment of, 43-44
- indications for transfusion in, 46-47
- IV IgG for, 92-93
- microaggregate filters for, 52
- multi-pack systems for, 45
- neutrophils for, 49-52
- platelet concentrates for, 47-49
- preferred red cell product for, 47
- red cell concentrates for, 39-44
- short drawn units for, 45-46
- syringe system for, 45
- transfusion therapy for, 39-54
- Neutropenia, neonatal, 49-52
- Neutrophil transfusion therapy, for neonates, 49-52
- Non-A, and non-B hepatitis virus
 - discovery of, 77-80
 - enterically transmitted, 78
 - IV IgG transmission of, 110
- Nou, *see* Rh44
- Nutricel, 47

- OK^a, 17, 18-20
- Oncogene, 24-26
 - see also* Protooncogene
- Oral contraceptive, ATIII and, 257
- Oxygen, available, measurement of, 41
- Oxygen dissociation curve, 237-240
- Oxygen therapy, for neonates, 42

- Paroxysmal cold hemoglobinuria, acute, 219-227
 - differential diagnosis of, 226
 - serological findings in, 224-226
 - treatment for, 226-227
- Paroxysmal nocturnal hemoglobinuria
 - DAF and, 14-15
 - LAF-3 and, 13-14
- Pasteurization, for ATIII concentrates, 254
- PCH, *see* Paroxysmal cold hemoglobinuria
- PDGF, sis gene and, 35-36
- Percutaneous intrauterine umbilical blood sampling, 48
- Perioperative blood transfusion, tumor growth and, 243-250
 - see also* Tumor growth, transfusion-induced
- Perioperative hemodilution, for autologous transfusion, 294-296
- Perioperative red cell transfusion, 63-66
 - alternatives to, 65-66
 - anemia and, 63-64
 - criteria for, 63-64
 - future trends for, 66
 - risks of, 65
- Phagocytosis, 282
 - see also* Fc gamma receptor(s)
- Phlebotomy, for perioperative hemodilution, 295

- Plasminogen activator inhibitor, 265-266
- Platelets
 - collection of, 293
 - Fc gamma receptors on, 285
 - IgG effect on, 108
- Platelet transfusion
 - for neonates, 47-49
 - see also* Leukocyte-depleted red cells and platelets
- PMN, *see* Neutrophil transfusion therapy
- PNH, *see* Paroxysmal nocturnal hemoglobinuria
- Polyagglutinability, lectins and, 59
- Polycythemia, oxygen transport in, 240-241
- Polypeptides, Rh, 8-9
- Pr antigens, cold agglutination, 152-156
- Pregnancy, inherited ATIII deficiency and, 255-256
- Premature infant
 - IV IgG for, 92-93
 - poor weight gain in, 41-42
 - transfusion therapy for, 39-54
- Protein C inhibitor, 265-266
- Proteins, lectins as, 55
- Protooncogene
 - cell differentiation and, 24-38
 - definition of, 24-26
 - fos gene as, 31-34
 - future studies of, 36
 - myb gene as, 31
 - myc gene as, 26-31
 - ras gene as, 34-35
 - sis gene as, 35-36
- PUBS, *see* Percutaneous intrauterine umbilical blood sampling
- Pyridoxalated polyhemoglobin, 214-215, 216

- RBC antigens, *see* Red cell antigens
- RCM, *see* Red cell mass
- RE, *see* Reticuloendothelial system
- Red cell antigens, in renal allograft survival, 172-175
- Red cell concentrates, tumor growth and, 248
- Red cell freezing, 187-188
- Red cell mass, 237
 - measurement of, 41
- Red cell membrane, abnormal, lectins and, 58
- Red cell membrane glycoprotein(s), 13-23
 - BRIC 125 as, 16-17
 - CD44 as, 15-16
 - DAF as, 14-15
 - 12E7 as, 17-18
 - Fib 75.1 as, 17-18
 - general consideration for, 18-20
 - LFA-3 as, 13-14
 - OK^a as, 17
- Red cell production, 238
- Red cell substitute, 213-216
- Red cell transfusion
 - for neonates, 39-44
 - perioperative, 63-66
 - see also* Leukocyte-depleted red cells and platelets
- Rejuvenation, red cell, 125
- Renal cell carcinoma, effect of blood transfusion on, 247
- Renal transplantation, 171-177

- ABO antigens and, 172-174
 - cyclosporine and, 172, 176
 - factors in allograft survival, 171, 172
 - frozen red cells and, 124
 - HLA antigens and, 171-172, 173
 - Lewis system and, 173-174
 - mechanism of blood transfusion for, 176-177
 - platelet transfusion and, 183-184
 - pretransplantation transfusion and, 175-176, 183-185
 - RBC antigens and, 172-175
 - Reticuloendothelial blockade, in ITP, 107
 - Reticuloendothelial system, 83-85
 - Retrovirus, 24
 - Rg antigen, antibodies to, 133-134
 - Rh32, 2-3, 5, 6
 - Rh40, 2, 6
 - Rh41, 2-3, 6
 - Rh42, 3, 6
 - Rh43, 3-4, 6
 - Rh44, 4, 6
 - Rh45, 4-5, 6
 - Rh46, 5, 6
 - Rh47, 5-6
 - Rh blood group system, 1-12
 - biochemistry of, 7-9
 - characteristics of, 2-6
 - cluster model in, 9
 - general considerations for, 1-2
 - gene structure of, 1-2
 - genetics of, 9-10
 - isolation of, 7-9
 - LFA-3 and, 14
 - rare antigens in, 6-7
 - Rheumatoid arthritis, IL-1 and, 200
 - Rh_{null}, BRIC 125 glycoprotein and, 16
 - Rh polypeptides, 8-9
 - Rh proteins, 8
 - Rh1 to Rh3, 2-3
 - Riv, *see* Rh45
 - RNA viruses, oncogenic, 24
 - see also* Protooncogene
 - R^{cooh}, 6-7
 - Rubella, cold agglutination and, 141
-
- Sa antigens, cold agglutination and, 156-157
 - Sarcoma virus
 - leukemia virus and, 24
 - oncogenesis by, 24-25
 - Saul, 7
 - Scianna blood group system, LFA-3 and, 14
 - Sec, *see* Rh46
 - Secretor tests, lectins in, 57
 - Serpins, 253, 264-265
 - Sialic acid specific lectins, 60
 - Sis gene, 35-36
 - Soft tissue sarcoma, effect of blood transfusion on, 247
 - Sports anemia, 241
 - Staph protein, Rh, 8-9
 - Suppressor T cell, 183-186
 - induction of, 177
 - Tar, *see* Rh40
 - Targett, *see* Rh40
 - T-helper cell, 181
 - Thrombin
 - inhibition of, 264-265
 - see also* Antithrombin III deficiency
 - Thrombocytopenia
 - IV IgG for, 96
 - neonatal, transfusion therapy for, 47-49
 - see also* Idiopathic thrombocytopenic purpura
 - Thromboembolism
 - ATIII deficiency and, 254-256
 - see also* Antithrombin III deficiency
 - T lymphocyte
 - function of, 194
 - IL-1 and, 197-198
 - LFA-3 binding to, 13
 - TNF, *see* Tumor necrosis factor
 - Transfusion filter, 52
 - Transplantation, *see* Renal transplantation
 - Tumor growth, transfusion-induced, 243-250
 - animal experiments of, 243-244
 - breast cancer and, 246
 - cervix carcinoma and, 247
 - clinical studies of, 244-247
 - colorectal carcinoma and, 244-246
 - gastric cancer and, 247
 - limitations of studies of, 249-250
 - lung cancer and, 246-247
 - mechanisms responsible for, 248-249
 - renal cell carcinoma and, 247
 - soft tissue sarcoma and, 247
 - variables concerning, 247-248, 249
 - valva carcinoma and, 247
 - Tumor necrosis factor, IL-1 and, 199
-
- Ulex europaeus*, 57
 - Ultraviolet radiation, leukocyte depletion and, 182, 185
 - UV irradiation, *see* Ultraviolet radiation
-
- Vicia graminea*, 57
 - Viral transmission
 - frozen red cells and, 124-125
 - IgG and, 109-111
 - leukocyte-depleted red cells and platelets and, 188-189
 - Vo antigens, cold agglutination and, 152
 - VTE, *see* Antithrombin III deficiency; Familial venous thromboembolism
 - Valva carcinoma, effect of blood transfusion on, 247
-
- Whole blood transfusion, 43
 - for neonate, 46-47
 - tumor growth and, 248
 - Wiener model, 9-10
 - World Health Organization, guidelines for IV IgG, 86
-
- Xg blood group system, 12E7 and, 17
 - Yk^a antigen, antibodies to, 128-130